Abstract
Optimization of the lead compound 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2,3-dihydro-indol-1-yl)-ethanone 1 by systematic structure-activity relation (SAR) studies lead to two potent compounds 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)-ethanone 2n and 2-[-4-(4-chloro-benzyl)-piperazin-1-yl]-1-(2-methy-2,3-dihydro-indol-1-yl)-ethanone 7b. Their related synthesis was also reported.
MeSH terms
-
Animals
-
Binding, Competitive / drug effects
-
Dopamine Antagonists / chemical synthesis*
-
Dopamine Antagonists / pharmacology*
-
Dopamine D2 Receptor Antagonists*
-
Glycine / chemistry
-
Humans
-
In Vitro Techniques
-
Indoles / chemical synthesis*
-
Indoles / pharmacology*
-
Piperazines / chemical synthesis*
-
Piperazines / pharmacology*
-
Prazosin / metabolism
-
Rats
-
Receptors, Dopamine D4
-
Recombinant Proteins / drug effects
-
Structure-Activity Relationship
Substances
-
2-(-4-(4-chloro-benzyl)-piperazin-1-yl)-1-(2,3-dihydro-indol-1-yl)-ethanone
-
2-(-4-(4-chloro-benzyl)-piperazin-1-yl)-1-(2-methy-2,3-dihydro-indol-1-yl)-ethanone
-
DRD4 protein, human
-
Dopamine Antagonists
-
Dopamine D2 Receptor Antagonists
-
Drd4 protein, rat
-
Indoles
-
Piperazines
-
Recombinant Proteins
-
Receptors, Dopamine D4
-
Glycine
-
Prazosin